Mitosin and DNA topoisomerase IIα: Two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival

Applied Immunohistochemistry and Molecular Morphology

Volumn 9, Issue 3, 2001, Pages 207-214

  Korkolopoulou, P ^a   Patsouris, E ^a   Konstantinidou, A E ^a   Christodoulou, P ^a   Thomas Tsagli, E ^a   Kouzelis, K ^a   Angelidakis, D ^a   Rologis, D ^a   Davaris, P ^a  

^a NONE   (Greece)

Author keywords

Astrocytomas; Immunohistochemistry; Mitosin; Survival; Topo II

Indexed keywords

CYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MITOSIN; PHOSPHOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, NEOPLASM; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICROFILAMENT PROTEINS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 0034850421     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200109000-00003     Document Type: Article

References (32)

1. Astrocytic neoplasms
2. Prognostic implications of the proliferative potential of low-grade astrocytomas
3. Characterization of a novel 350-kilodalton nuclear phoshoprotein that is specifically involved in mitotic-phase progression
4. The C-terminus of mitosin is essential for its nuclear localization, centromere/cinetochore targeting, and dimerization
5. Structure and function of type II DNA topoisomerases
6. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
7. DNA topoisomerases as anticancer drug targets
8. The new WHO classification of brain tumours
9. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relations and prognostic value
10. Immunohistochemical staining of DNA topoisomerase IIα in human gliomas
11. Proliferating cell nuclear antigen expression in the survival of astrocytoma patients
12. Comparison of three quantitation methods for PCNA immunostaining: Applicability and relation to survival in 83 astrocytic neoplasms
13. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Prognostic significance
14. The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors
15. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma
16. Prognostic implications of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumours
17. Prog]nostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas
18. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms
19. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and Sphase fraction using archival paraffin-embedded samples
20. Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: Its prognostic significance
21. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas
22. Immunohistochemical demonstration of proliferating cell nuclear antigen in glioblastomas: Pronounced heterogeneity and lack of prognostic significance
23. Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme
24. The complexities of proliferating cell nuclear antigen
25. Effect of fixation time and microwaveoven heating time on retrieval of the Ki-67 antigen from paraffinembedded tissue
26. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study
27. Mitosin (a new proliferation marker) correlates with clinical outcome in nodenegative breast cancer
28. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen?
29. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system. Correlation with MIB-1 expression and patient survival
30. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues
31. Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer
32. The cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat-shock or ionizing radiation